Skye Bioscience, Inc. Common Stock (SKYE) — Cash Flow-to-Debt Ratio
Skye Bioscience, Inc. Common Stock (SKYE) has a Cash Flow-to-Debt Ratio of -0.62x as of June 2026, meaning its operating cash flow of $-7.12 Million could theoretically repay -1% of its total liabilities ($11.53 Million) in one year. See financial agility of Skye Bioscience, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Skye Bioscience, Inc. Common Stock Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Skye Bioscience, Inc. Common Stock across 14 annual periods. For the full cash flow conversion analysis, see SKYE cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Skye Bioscience, Inc. Common Stock (2012–2025)
Year-by-year debt coverage analysis for Skye Bioscience, Inc. Common Stock. Check SKYE cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.19x | $-43.06 Million | $8.29 Million | ▲ +5.1% |
| 2024 | -5.47x | $-25.24 Million | $4.61 Million | ▼ -451.9% |
| 2023 | -0.99x | $-13.95 Million | $14.07 Million | ▲ +5.7% |
| 2022 | -1.05x | $-12.74 Million | $12.12 Million | ▲ +35.2% |
| 2021 | -1.62x | $-6.47 Million | $3.99 Million | ▲ +40.5% |
| 2020 | -2.73x | $-6.05 Million | $2.22 Million | ▲ +34.5% |
| 2019 | -4.16x | $-6.03 Million | $1.45 Million | ▼ -1748.8% |
| 2018 | -0.23x | $-3.94 Million | $17.52 Million | ▲ +90.7% |
| 2017 | -2.43x | $-3.30 Million | $1.36 Million | ▼ -21.3% |
| 2016 | -2.00x | $-3.55 Million | $1.77 Million | ▼ -63.3% |
| 2015 | -1.23x | $-3.73 Million | $3.04 Million | ▲ +44.0% |
| 2014 | -2.19x | $-1.76 Million | $801.89K | ▼ -2650.6% |
| 2013 | -0.08x | $-14.49K | $182.15K | ▼ -117.9% |
| 2012 | 0.45x | $1.93K | $4.33K | — |